ZA200200539B - Xenon and nmda agonist. - Google Patents

Xenon and nmda agonist. Download PDF

Info

Publication number: ZA200200539B
Authority: ZA; South Africa
Prior art keywords: xenon; nmda; cells; nmda receptor; synaptic
Prior art date: 1999-07-29

Application number

ZA200200539A

Other languages

English (en)

Inventor

Franks Nicholas Peter

Mervyn Maze

Original Assignee

Protexeon Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-29

Filing date

2002-01-22

Publication date

2002-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10858166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200200539(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-01-22 Application filed by Protexeon Ltd filed Critical Protexeon Ltd

2002-09-25 Publication of ZA200200539B publication Critical patent/ZA200200539B/en

Links

229910052724 xenon Inorganic materials 0.000 title claims abstract description 129
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 title claims abstract description 129
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 29
239000000556 agonist Substances 0.000 title description 4
230000000694 effects Effects 0.000 claims abstract description 57
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims abstract description 39
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims abstract description 38
238000000034 method Methods 0.000 claims abstract description 21
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 8
230000008569 process Effects 0.000 claims abstract description 8
230000003956 synaptic plasticity Effects 0.000 claims description 15
239000003085 diluting agent Substances 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 10
230000004112 neuroprotection Effects 0.000 claims description 10
230000004913 activation Effects 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 8
230000032611 negative regulation of synaptic plasticity Effects 0.000 claims description 8
230000006872 improvement Effects 0.000 claims description 6
241000124008 Mammalia Species 0.000 abstract description 11
210000004027 cell Anatomy 0.000 description 39
208000014674 injury Diseases 0.000 description 22
208000027418 Wounds and injury Diseases 0.000 description 21
230000006378 damage Effects 0.000 description 21
230000002401 inhibitory effect Effects 0.000 description 20
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 19
239000007789 gas Substances 0.000 description 19
229930195712 glutamate Natural products 0.000 description 19
230000000946 synaptic effect Effects 0.000 description 19
230000002964 excitative effect Effects 0.000 description 18
239000000243 solution Substances 0.000 description 18
230000001242 postsynaptic effect Effects 0.000 description 16
230000004044 response Effects 0.000 description 16
102000030621 adenylate cyclase Human genes 0.000 description 15
108060000200 adenylate cyclase Proteins 0.000 description 15
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 15
102000003855 L-lactate dehydrogenase Human genes 0.000 description 14
108700023483 L-lactate dehydrogenases Proteins 0.000 description 14
229960003692 gamma aminobutyric acid Drugs 0.000 description 14
230000001537 neural effect Effects 0.000 description 14
230000001404 mediated effect Effects 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
210000002569 neuron Anatomy 0.000 description 11
230000003444 anaesthetic effect Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
230000000848 glutamatergic effect Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
229960002748 norepinephrine Drugs 0.000 description 8
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 7
230000008859 change Effects 0.000 description 7
230000000763 evoking effect Effects 0.000 description 7
210000004295 hippocampal neuron Anatomy 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
230000009471 action Effects 0.000 description 6
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 6
238000003501 co-culture Methods 0.000 description 6
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 6
230000003371 gabaergic effect Effects 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
238000012546 transfer Methods 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
229940099433 NMDA receptor antagonist Drugs 0.000 description 5
229940124326 anaesthetic agent Drugs 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000012085 test solution Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
210000000225 synapse Anatomy 0.000 description 4
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000036592 analgesia Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012258 culturing Methods 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
239000006145 Eagle's minimal essential medium Substances 0.000 description 2
102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000002999 depolarising effect Effects 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000006870 function Effects 0.000 description 2
238000004868 gas analysis Methods 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000003961 neuronal insult Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
238000005192 partition Methods 0.000 description 2
238000007747 plating Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
230000009782 synaptic response Effects 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
241001535291 Analges Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241001559589 Cullen Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
231100000491 EC50 Toxicity 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
102000011714 Glycine Receptors Human genes 0.000 description 1
108010076533 Glycine Receptors Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000015592 Involuntary movements Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
240000003186 Stachytarpheta cayennensis Species 0.000 description 1
235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000002397 epileptogenic effect Effects 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000003445 gaba agent Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
210000001362 glutamatergic neuron Anatomy 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000010365 information processing Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000001535 kindling effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000000478 neocortex Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
230000036515 potency Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
229960004134 propofol Drugs 0.000 description 1
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
230000002385 psychotomimetic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
210000003925 spinal cord interneuron Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 1
229960005453 strychnine Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200200539A 1999-07-29 2002-01-22 Xenon and nmda agonist. ZA200200539B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9917822.0A GB9917822D0 (en)	1999-07-29	1999-07-29	Nmda antagonist

Publications (1)

Publication Number	Publication Date
ZA200200539B true ZA200200539B (en)	2002-09-25

Family

ID=10858166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200200539A ZA200200539B (en)	1999-07-29	2002-01-22	Xenon and nmda agonist.

Country Status (13)

Country	Link
US (1)	US6274633B1 (de)
EP (1)	EP1200103B1 (de)
JP (1)	JP5088997B2 (de)
AT (1)	ATE404211T1 (de)
AU (1)	AU778097B2 (de)
CA (1)	CA2280310C (de)
DE (1)	DE60039878D1 (de)
ES (1)	ES2311466T3 (de)
GB (1)	GB9917822D0 (de)
PT (1)	PT1200103E (de)
RU (1)	RU2257902C2 (de)
WO (1)	WO2001008692A1 (de)
ZA (1)	ZA200200539B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
ES2211151T3 (es)	1998-08-19	2004-07-01	Skyepharma Canada Inc.	Dispersiones acuosas inyectables de propofol.
DE19910986C2 (de) *	1999-03-11	2001-06-07	Aga Ab	Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) *	1999-06-11	1999-08-11	Imperial College	Formulation
EP1436258A4 (de) *	2001-03-08	2005-03-23	Univ Emory	Ph-wert-abhängige nmda-rezeptorantagonisten
GB0209998D0 (en) *	2002-05-01	2002-06-12	Protexeon Ltd	Use
GB0210021D0 (en)	2002-05-01	2002-06-12	Air Prod & Chem	Ultrasonic gas analyser
GB0218153D0 (en) *	2002-08-05	2002-09-11	Ic Innovations Ltd	An analgesic agent for newborn or retal subjects
US7681572B2 (en) *	2002-08-20	2010-03-23	Aga Ab	Method and devices for administration of therapeutic gases
US7337776B2 (en) *	2002-08-20	2008-03-04	Aga Ab	Methods for easing pain and anxiety from atrial or ventricular defibrillation
FR2858233B1 (fr) *	2003-07-30	2008-04-11	Air Liquide Sante Int	Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
WO2005034966A1 (en) *	2003-10-10	2005-04-21	Protexeon Limited	Use of xenon with hypothermia for treating neonatal asphyxia
EP1675597A2 (de) *	2003-10-21	2006-07-05	Aga Ab	Verwendung von xenon zur prävention von programmiertem zelltod
FR2863169B1 (fr) *	2003-12-08	2006-02-10	Air Liquide Sante Int	Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
GB0520176D0 (en) *	2005-10-04	2005-11-09	Imp College Innovations Ltd	Use
RU2346695C2 (ru) *	2006-08-15	2009-02-20	Общество с ограниченной ответственностью "Ксиан"(ООО "Ксиан")	Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса
EP1980260A1 (de)	2007-04-10	2008-10-15	Nicholas Peter Franks	Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
EP1980261A1 (de)	2007-04-10	2008-10-15	Nicholas Peter Franks	Verwendung von Helium mit Sauerstoff zur Bereitstellung von Neuroprotektion
US8435569B2 (en) *	2007-04-30	2013-05-07	Nnoxe Pharmaceutiques Inc.	Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
KR20100045983A (ko)	2007-06-29	2010-05-04	에모리 유니버시티	신경보호를 위한 ｎｍｄａ 수용체 길항물질
FR2952305B1 (fr) *	2009-11-10	2012-04-27	Air Liquide	Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
CN103565745A (zh)	2012-08-10	2014-02-12	德克萨斯州大学系统董事会	用于治疗中风的神经保护性脂质体组合物和方法
CA3132914C (en)	2013-03-15	2023-11-07	The Board Of Regents Of The University Of Texas System	Liquids rich in noble gas and methods of their preparation and use
FR3022456B1 (fr) *	2014-06-20	2016-07-15	Air Liquide	Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU120307A1 (ru) *	1949-04-19	1958-11-30	К.М. Салдадзе	Способ приготовлени искусственно-радиоактивных лечебных ванн
SU1075632A1 (ru) *	1982-05-25	1985-06-30	Ордена Трудового Красного Знамени Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср	Устройство дл моделировани нейрона
US5124319A (en) *	1991-10-11	1992-06-23	American Home Products Corporation	Benzimidazole phosphono-amino acids
JP4313435B2 (ja) *	1995-07-24	2009-08-12	トラスティーズオブボストンユニバーシティー	プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
DE19709704C2 (de) *	1997-03-10	1999-11-04	Michael Georgieff	Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
GB9706294D0 (en) *	1997-03-26	1997-05-14	Glaxo Wellcome Spa	Heterocyclic compound
DE69809827D1 (de) *	1997-03-31	2003-01-16	Korea Res Inst Chem Tech	Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
JPH1171271A (ja) *	1997-06-27	1999-03-16	Shionogi & Co Ltd	グルコン酸又はその類縁体を含有するｎｍｄａ受容体拮抗剤
DE19910986C2 (de) *	1999-03-11	2001-06-07	Aga Ab	Verwendung von Xenon bei der Behandlung von Neurointoxikationen

1999
- 1999-07-29 GB GBGB9917822.0A patent/GB9917822D0/en not_active Ceased
- 1999-08-13 CA CA002280310A patent/CA2280310C/en not_active Expired - Lifetime
- 1999-08-23 US US09/378,806 patent/US6274633B1/en not_active Expired - Lifetime
2000
- 2000-07-28 PT PT00948171T patent/PT1200103E/pt unknown
- 2000-07-28 DE DE60039878T patent/DE60039878D1/de not_active Expired - Lifetime
- 2000-07-28 RU RU2002105377/15A patent/RU2257902C2/ru not_active IP Right Cessation
- 2000-07-28 JP JP2001513422A patent/JP5088997B2/ja not_active Expired - Lifetime
- 2000-07-28 EP EP00948171A patent/EP1200103B1/de not_active Revoked
- 2000-07-28 WO PCT/GB2000/002896 patent/WO2001008692A1/en not_active Ceased
- 2000-07-28 ES ES00948171T patent/ES2311466T3/es not_active Expired - Lifetime
- 2000-07-28 AU AU61735/00A patent/AU778097B2/en not_active Ceased
- 2000-07-28 AT AT00948171T patent/ATE404211T1/de not_active IP Right Cessation
2002
- 2002-01-22 ZA ZA200200539A patent/ZA200200539B/en unknown

Also Published As

Publication number	Publication date
DE60039878D1 (de)	2008-09-25
CA2280310A1 (en)	2001-01-29
ATE404211T1 (de)	2008-08-15
AU6173500A (en)	2001-02-19
EP1200103A1 (de)	2002-05-02
ES2311466T3 (es)	2009-02-16
US6274633B1 (en)	2001-08-14
GB9917822D0 (en)	1999-09-29
RU2257902C2 (ru)	2005-08-10
JP5088997B2 (ja)	2012-12-05
AU778097B2 (en)	2004-11-18
PT1200103E (pt)	2008-09-17
JP2003505512A (ja)	2003-02-12
EP1200103B1 (de)	2008-08-13
WO2001008692A1 (en)	2001-02-08
CA2280310C (en)	2008-10-14

Publication	Publication Date	Title
AU778097B2 (en)	2004-11-18	Xenon an NMDA antagonist
US6653354B2 (en)	2003-11-25	NMDA antagonist comprising xenon
Cechetto et al.	2001	The effects of propofol in the area postrema of rats
de Sousa et al.	2000	Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon
Takei et al.	1999	Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors
Lopshire et al.	1998	The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies
CA1220719A (en)	1987-04-21	Celiprolol for the treatment of glaucoma
Diamond et al.	1983	In vivo bronchodilator activity of vasoactive intestinal peptide in the cat
McLoughlin et al.	1992	Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens
Raszkiewicz et al.	1992	Nitric oxide synthase is critical in mediating basal forebrain regulation of cortical cerebral circulation
CA2118314A1 (en)	1994-09-01	Methods for treating arteriosclerosis
Cardell et al.	1998	Carbon monoxide, a cyclic GMP-related messenger, involved in hypoxic bronchodilation in vivo
Hirota et al.	1997	Sevoflurane modulates both GABAA and GABAB receptors in area CA1 of rat hippocampus
Ferko et al.	1977	Induction of physical dependence in rats by ethanol inhalation without the use of pyrazole
Sasaki et al.	1990	Involvement of the entopeduncular nucleus and the habenula in methamphetamine-induced inhibition of dopamine neurons in the substantia nigra of rats
Cohen et al.	1996	Nitric oxide regulates endothelium-dependent vasodilator responses in rabbit hindquarters vascular bed in vivo
Lohinai et al.	1999	Nitric oxide modulates salivary amylase and fluid, but not epidermal growth factor secretion in conscious rats
US6525017B1 (en)	2003-02-25	Using glutathiane to protect neurons from injury
Heaslip et al.	1994	Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.
Zheng et al.	2019	α1G T-type calcium channel determines the angiogenic potential of pulmonary microvascular endothelial cells
KRISHNA et al.	1977	Mechanisms of chronotropic effects of volatile inhalation anesthetics
Radius et al.	1973	Cyclic-AMP and the ocular responses to norepinephrine
Dickinson et al.	2002	Selective synaptic actions of thiopental and its enantiomers
Kolesnick	1990	1, 2-Diacylglycerols overcome cyclic AMP-mediated inhibition of phosphatidylcholine synthesis in GH3 pituitary cells
Steketee	1998	Repeated injection of GBR 12909, but not cocaine or WIN 35,065-2, into the ventral tegmental area induces behavioral sensitization